Treatment of Benign Prostatic Hyperplasia

被引：26

作者：

Pinheiro, Luis Campos ^{[1
]}

Pisco, Joao Martins ^{[1
]}

机构：

[1] St Louis Hosp, Dept Intervent Radiol, Rua Luz Soriano 182, P-1200249 Lisbon, Portugal

来源：

TECHNIQUES IN VASCULAR AND INTERVENTIONAL RADIOLOGY | 2012年 / 15卷 / 04期

关键词：

benign prostatic hyperplasia; BPH medical treatment; BPH surgery; BPH minimal invasive treatments;

D O I：

10.1053/j.tvir.2012.09.004

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Lower urinary tract symptoms (LUTS) may be a sign of aging rather than a consequence of benign prostatic enlargement (BPE) or benign prostatic obstruction (BPO). Medical or invasive treatments should address the bothersome symptoms and the quality of life of patients. Alpha blockers and 5 -alpha reductase inhibitors are most frequently used in benign prostatic hyperplasia (BPH) medical treatments, whereas Transurethral Resection of the Prostate (TURP) remains the "gold standard" for surgical treatments. Several minimal invasive treatments are emerging with promising outcomes. (C) 2012 Published by Elsevier Inc.

引用

页码：256 / 260

页数：5

共 30 条

[1] A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder
Chapple, CR
Roehrborn, CG
[J]. EUROPEAN UROLOGY, 2006, 49 (04) : 651 - 659
[2] EAU Guidelines, 2010, 25 EAU ANN C BARC
[3] Holmium laser enucleation of the prostate: Results at 6 years
Gilling, Peter J.
Aho, Tevita F.
Frampton, Christopher M.
King, Colleen J.
Fraundorfer, Mark R.
[J]. EUROPEAN UROLOGY, 2008, 53 (04) : 744 - 749
[4] Holmium:YAG laser resection of prostate (HoLRP) for patients in urinary retention
Kabalin, JN
Mackey, MJ
Cresswell, MD
Fraundorfer, MR
Gilling, PJ
[J]. JOURNAL OF ENDOUROLOGY, 1997, 11 (04) : 291 - 293
[5] Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men
Kawabe, Kazuki
Yoshida, Masaki
Homma, Yukio
[J]. BJU INTERNATIONAL, 2006, 98 (05) : 1019 - 1024
[6] Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
Lepor, H
[J]. UROLOGY, 1998, 51 (06) : 892 - 900
[7] Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia
Lucas, MG
Stephenson, TP
Nargund, V
[J]. BJU INTERNATIONAL, 2005, 95 (03) : 354 - 357
[8] Tamsulosin - An update of its role in the management of lower urinary tract symptoms
Lyseng-Williamson, KA
Jarvis, B
Wagstaff, AJ
[J]. DRUGS, 2002, 62 (01) : 135 - 167
[9] Age related urodynamic changes in patients with benign prostatic hyperplasia
Madersbacher, S
Klingler, HC
Schatzl, G
Stulnig, T
Schmidbauer, CP
Marberger, M
[J]. JOURNAL OF UROLOGY, 1996, 156 (05) : 1662 - 1667
[10] The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
McConnell, JD
Bruskewitz, R
Walsh, P
Andriole, G
Lieber, M
Holtgrewe, HL
Albertsen, P
Roehrborn, CG
Nickel, JC
Wang, DZ
Taylor, AM
Waldstreicher, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (09) : 557 - 563

← 1 2 3 →